The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare

Is Drug Repurposing the new breakthrough for faster approval of Psychedelic-assisted treatments? In this TDR Psychedelic Exclusive, we speak with the CEO of Algernon Pharmaceuticals (CNSX: AGN) (OTC: AGNPF) Christopher Moreau who explains the company’s recent...

Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT

CEO Christopher J. Moreau provides an update on Algernon Pharmaceuticals Inc. announcement that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188...

Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT

Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or...

Contact Us

(255) 352-6258

1234 Divi St. #1000
San Francisco, CA 94220

Visit Us

Monday: 9am–4pm
Tuesday: 9am–4pm
Wednesday: 9am–4pm
Thursday: 9am–4pm
Friday: 8am–2pm

Weekends: Closed

Subscribe for 15% Off Your First Order